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LETTERS TO THE EDITOR
Critical Care for
Patients with Lung
Cancer
To the Editor:
I read with interest the recently
published concise review by Soubani
and Ruckdeschel,1 which described the
main indications for critical care for pa-
tients with lung cancer and discusses
recent data on their outcome and predic-
tors from which patients with lung can-
cer are likely to benefit.
The outcome of patients with lung
cancer admitted to the intensive care
unit (ICU) has improved. Recently, Tof-
fart et al.2 described 103 consecutive
nonsurgical patients with lung cancer
admitted to three ICUs in France. In this
study,2 patients who had a poor perfor-
mance status (PS) at baseline or who
developed multiorgan failure early after
ICU admission had significantly higher
mortality rates with a survival of 37%
after 90 days.
During the past 3 years, several
studies2–4 have reported the outcomes of
critically ill patients with lung cancer
admitted to ICU. These studies2–4 in-
cluded a total of 347 patients, and the
ICU and in-hospital mortality rate for
these patients were 32% and 47.3%,
respectively. Two of these studies2,3 re-
ported, 144/208 (69.2%) patients with
stages IIIB/IV and 130/208 (62.5%) pa-
tients with metastasis at ICU admission
(n  63)2 or whether already known or
evidenced within the first week of ICU
stay (n  67).3 The factors associated
with increased mortality in this group of
critically ill patients with cancer are
poor PS,2,3 organ dysfunction,2–4 and
metastasis at admission to ICU.2 Specif-
ically, in this subgroup of critically ill
patients with cancer, PS might be a sim-
ple tool for oncologists and intensivists
as an aid for admitting patients with
lung cancer to the ICU.3 On the other
hand, the course of organ dysfunction
during the first 3 days of ICU stay could
be useful for considering treatment lim-
itation.2 The patients in whom potential
benefits from ICU admission are in
doubt should receive a trial of full-code
ICU management; this ICU trial has
been of help for resolving doubts and
conflicts surrounding ICU admission of
patients with cancer.5
Critically ill patients with lung
cancer admitted to the medical ICU
have often posed a high-mortality rate
but their outcome has been progres-
sively improving and is approximating
that of the general critically ill popula-
tion1; however, it should be considered
that early integration of palliative care
with standard oncologic care in patients
with metastatic non-small cell lung can-
cer led to significant improvements in
quality of life and mood.6
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Do Complex Mutations
of the Epidermal
Growth Factor
Receptor Gene Reflect
Intratumoral
Heterogeneity?
To the Editor:
In our clinical practice, two differ-
ent epidermal growth factor receptor
(EGFR) gene mutations are occasionally
found in a single tumor sample. Such
co-occurring EGFR mutations have
been termed “complex mutations,” and
we have previously reported the incidence
and efficacy of gefitinib for patients with
complex mutations.1 In our previous arti-
cle, we discussed the cause of complex
mutations and speculated on the existence
of intratumoral heterogeneity for EGFR
mutations. We recently encountered three
cases that support our hypothesis and
herein present these cases.
Case 1 was a 68-year-old man.
He received a computed tomography-
guided lung biopsy due to a suspicion of
lung cancer. We performed a fine needle
aspiration, followed by a core needle
biopsy through a guide needle to obtain
both cytological fluid and histological
tissue (Figure 1). Although both cytol-
ogy and histology revealed adenocarci-
noma cells, we accidentally performed
EGFR mutational analysis on both spec-
imens. Interestingly, only a point muta-
tion in exon 21 (L858R) was detected in
the cytology, but complex mutations con-
sisting of a point mutation in exon 18
(G719S) and L858R were detected in the
histology. After a diagnosis of locally ad-
vanced disease, the patient underwent
concurrent chemoradiation therapy. After
the treatment, he has been observed and
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has not yet received EGFR-tyrosine ki-
nase inhibitor (TKI) therapy.
Case 2 was a 66-year-old woman.
She was diagnosed with lung adeno-
carcinoma and underwent surgery as
the initial therapy. EGFR mutational
analysis in the surgical tissue revealed
complex mutations consisting of a de-
letional mutation in exon 19 (Del-19)
and L858R. After recurrence, she un-
derwent multiple chemotherapies in-
cluding EGFR-TKIs. In the course of
treatment, she complained of gait dis-
turbance and neck stiffness. Brain
magnetic resonance imaging showed
leptomeningeal metastases (Figure 2),
and a lumbar puncture was performed.
Unexpectedly, Del-19 disappeared, and
only L858R was detected by EGFR
mutational analysis of malignant cells
in the cerebral spinal fluid. Rechallenge
treatment with erlotinib was admin-
istered, and the clinical benefit has
continued for 4 months.
Case 3 was an 81-year-old man.
He was initially diagnosed with lung
adenocarcinoma with pleural dissemina-
tions. EGFR mutational analysis of the
primary tumor showed complex muta-
tions consisting of Del-19 and L858R.
Considering the patient’s age, gefitinib
was chosen as the first-line treatment.
Primary tumor and pleural dissemina-
tions markedly responded to gefitinib
for approximately 20 months. However,
the right pleural effusion has recently
increased (Figure 3), and the cytology
of pleural effusion revealed adenocarci-
noma cells. Similarly, Del-19 disap-
peared, and both L858R and a point
mutation in exon 20 (T790M) were de-
tected by EGFR mutational analysis of
the pleural effusion. Chest tube drainage
has been carried out.
Case 1 implies the existence of
heterogeneous EGFR mutations in a sin-
gle tumor: cytological fluid cells harbor-
ing only L858R and histological tissue
cells harboring both G719S and L858R
simultaneously existed in a single tu-
mor. The intratumoral heterogeneity of
EGFR mutation has been previously re-
ported; both EGFR mutated and wild-
type malignant cells were confirmed in a
single tumor tissue in the report.2 In
cases 2 and 3, although complex muta-
tions consisting of Del-19 and L858R
were detected at the initial EGFR muta-
tional analysis, Del-19 has disappeared
and L858R remained after EGFR-TKI
treatments. Higher sensitivity to EGFR-
TKIs in patients with Del-19 than
L858R has been demonstrated in several
reports.3 If Del-19 and L858R cells had
existed separately, Del-19 cells would
have responded to EGFR-TKIs better
than L858R cells, and L858R cells
might have remained.
FIGURE 1. Computed tomography-guided lung biopsy performed on the tumor
harboring complex mutations with G719S and L858R.
FIGURE 2. The magnetic resonance image shows findings of leptomeningeal me-
tastases (arrow heads).
FIGURE 3. Right pleural effusion con-
taining adenocarcinoma cells harboring
complex mutations with Del-19 and L858R,
and pleural disseminations are shown.
Journal of Thoracic Oncology • Volume 6, Number 6, June 2011 Letter to the Editor
Copyright © 2011 by the International Association for the Study of Lung Cancer 1145
Our present cases exhibiting these
complex mutations suggest the intratu-
moral heterogeneity of EGFR mutations.
Considering intratumoral heterogene-
ity consisting of EGFR-sensitive-mutated
cells and wild-type or EGFR-resistant-
mutated cells, the detection of EGFR mu-
tations using a highly sensitive polymer-
ase chain reaction method from small
biopsies may not always reflect whole
tumor sensitivity to EGFR-TKIs.4 How-
ever, our data were taken from only a few
cases, and further research is needed. The
clinical significance of intratumoral heter-
ogeneity warrants future studies.
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Evaluation of ALK Gene
Status in Primary Lung
Adenocarcinoma and
Matched Metastases
To the Editor:
On March 2010, because of a wors-
ening in his breathing ability, a heavy
smoking (40 pack/yr) 54-year-old man
performed a chest computed tomogra-
phy, which showed a left-sided pleural
effusion. A thoracoscopy showed multi-
ple pleural nodules, which were biop-
sied. The diagnosis was pleural metas-
tases from lung adenocarcinoma. The
percentage of tumor cells in the pleural
bioptical specimen was 60. The tumor
did not harbor neither the epidermal
growth factor receptor nor K-ras muta-
tions. Six cycles of cisplatin plus pem-
etrexed were administered with a partial
response. On November 2010, he re-
ceived a laparoscopy diagnosing perito-
neal metastases from lung adenocarci-
noma. The percentage of tumor cells in
the peritoneal bioptical specimen was
70. Sanger bidirectional sequencing did
not show epidermal growth factor recep-
tor and K-ras mutations. Two cycles of
gemcitabine plus docetaxel were admin-
istered with a progressive disease. On
December 2010, the presence of EML4-
ALK gene fusion was investigated. The
fluorescent in situ hybridization test was
performed on formalin-fixed and paraf-
fin-embedded tissue samples by using a
break-apart probe to ALK (ALK Dual
Color Probe of Vysis, Inc., Downers
Grove, IL). According to the score pro-
posed by Kwak et al.,1 the test was
considered negative in the pleural bi-
opsy (4% of the neoplastic cells with
split of the 5 and 3 probe signals),
whereas it was positive in the peritoneal
sample (15% of the scored tumor cells
had split of the 5 and 3 probe signals or
had isolated 3 signals). Unfortunately,
because of a rapid deterioration of the
clinical conditions, the patient was un-
able to receive any further therapy and
died on January 2011.
The EML4-ALK fusion gene pos-
sesses a potent oncogenic activity both
in vitro and in vivo and is detected in
approximately 3 to 5% of non-small cell
lung cancer, predominantly in patients
with adenocarcinoma and no or minimal
smoking history.1,2 These patients were
also found to be less responsive to plat-
inum-based chemotherapy and to have a
lower overall survival.3 Crizotinib, an
inhibitor of the tyrosine kinase activity
of both ALK and the met proto-oncogene,
demonstrated high activity in these pa-
tients.1 To the best of our knowledge, this
is the first report concerning a discrep-
ancy of the EML4-ALK gene detection
between primary and corresponding me-
tastases. The molecular basis for this
disparity is not known, but the evidence
of tumultuous growth in disease evolu-
tion might be related to a rapid change in
tumor biology. In our case, the EML4-
ALK fluorescent in situ hybridization
positivity was detected in a heavy smoker,
not a frequently characteristic, and the
onset of peritoneal metastasis, positive
for the EML4-ALK fusion gene, corre-
sponded to a worsening of prognosis as
expected. These observations may have
important clinical implications for the
molecular testing of targeted therapies,
calling for a much better selection of
patients and for the availability of met-
astatic tissue for the detection of the
presence of specific target to better ad-
dress the treatment.
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